Updated NICE Draft Recommendations

Share this article

Oncotype DX Breast Recurrence Score® Recommended in Draft Guidance by the National Institute for Health and Care Excellence (NICE) in the UK

Health officials from the National Institute for Health and Care Excellence (NICE) in the United Kingdom recently issued a revised recommendation that includes the use of the Oncotype DX Breast Recurrence Score® result to guide adjuvant chemotherapy decisions for early-stage breast cancer patients.

The new guidance was welcomed by the clinical community, patients, and patient advocates, including Baroness Delyth Morgan, chief executive of Breast Cancer Now, who said, “This major reversal represents real progress for patients. Prognostic tests like these are showing great potential to personalize breast cancer treatment and enable some women to be safely spared the grueling side effects of chemotherapy.”

As the only test proven to predict chemotherapy benefit, patients in the UK would benefit from knowing whether or not they could avoid unnecessary chemotherapy and its side effects. The final guidance from NICE is expected to be issued on September 12, 2018.

Oncotype DX My Colon Cancer Coach